

Special Issue

Research in Vaccine Adjuvants: Innovations and Challenges

Message from the Guest Editors

This Special Issue, "Research in Vaccine Adjuvants: Innovations and Challenges", aims to address these challenges and highlight the latest innovations in adjuvant research. We invite submissions on a variety of topics, including the following:

- New adjuvant materials and systems: exploring novel adjuvants derived from natural sources, synthetic polymers, or biotechnological approaches.
- Mucosal vaccine adjuvants: investigation of adjuvants that enhance the immunogenicity of mucosal vaccines, which are essential for the prevention of infection at mucosal surfaces.
- Mechanisms of adjuvant action: the study of the underlying mechanisms by which adjuvants interact with the immune system to enhance vaccine responses.
- Adjuvant safety and tolerability: evaluating the safety and tolerability of new adjuvants in preclinical and clinical studies.

We welcome original research articles, reviews, and perspectives that contribute to advancing our understanding of vaccine adjuvants. By addressing these topics, we aim to foster new insights and drive innovations in vaccine adjuvant research.

Guest Editors

Prof. Dr. Haibo Li

National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China

Prof. Dr. Hongwu Sun

National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, China

Deadline for manuscript submissions

20 October 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/222924

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).